Drug Profile
Research programme: parasitic disease therapeutics - Upstream Biosciences
Alternative Names: Antimalarials - Upstream Biosciences; Leishmaniasis therapies - Upstream Biosciences; Trypanosomiasis (African sleeping sickness) therapies - Upstream BiosciencesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Upstream Biosciences
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Leishmaniasis; Malaria; Trypanosomiasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Leishmaniasis in Africa
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria in Africa
- 16 Jul 2016 No recent reports of development identified for preclinical development in Trypanosomiasis in Africa